Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.42 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.41 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454516 | 0.96 | HDAC1 (0.53) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL29367901 | 0.96 | HDAC1 (0.53) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL20897346 | 0.92 | HDAC1 (0.56) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL19958136 | 0.84 | HDAC1 (0.52) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL1679777 | 0.84 | HDAC1 (0.47) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL19582860 | 0.82 | HDAC1 (0.56) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL14443343 | 0.81 | HDAC1 (0.57) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL5484016 | 0.80 | HDAC1 (0.42) | HDAC1HDAC8PLOD2KMT2APLOD3 | |
| SCHEMBL3933153 | 0.80 | HDAC1 (0.50) | HDAC1HDAC8PLOD2KMT2AF7 | |
| SCHEMBL18106043 | 0.79 | HDAC1 (0.52) | HDAC1HDAC8PLOD2KMT2AF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394592-B2 | Methods for assessing cancer susceptibility to carcinogens in tobacco products | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-03-12 | — | — | US | claimed |
| US-20100173289-A1 | Methods for Assessing Cancer Susceptibility to Carcinogens in Tobacco Products | THE BOARD OF REGENTS, OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | claimed |
| US-20250305030-A1 | DNA ADDUCTOMICS BY MASS TAG PRELABELING | UNIV NORTHEASTERN (US) | 2025-10-02 | — | — | US | disclosed |
| US-12359243-B2 | DNA adductomics by mass tag prelabeling | NORTHEASTERN UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3865212-B1 | MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION | UNIV BRITISH COLUMBIA (CA) | 2024-03-13 | — | — | EP | disclosed |
| US-20220241226-A1 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | UNIV SOUTH FLORIDA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11337944-B2 | Method of treating colorectal cancers using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210340603-A1 | DNA ADDUCTOMICS BY MASS TAG PRELABELING | NORTHEASTERN UNIVERSITY | 2021-11-04 | — | — | US | disclosed |
| EP-3865212-A1 | MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION | The University of British Columbia (CA) | 2021-08-18 | — | — | EP | disclosed |
| EP-2978855-B1 | MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION | UNIV BRITISH COLUMBIA (CA) | 2021-01-13 | — | — | EP | disclosed |
| US-10725024-B2 | Microfluidic devices and methods for use thereof in multicellular assays of secretion | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-07-28 | — | — | US | disclosed |
| US-20030175372-A1 | New method for producing antioxidant and prevention of cancer | LIU YAGUANG (US) | 2003-09-18 | — | — | US | disclosed |
| US-20030152647-A1 | Safe botanical drug for treating malignant pleural effusion and cancer and increasing immune function | LIU YAGUANG (US) | 2003-08-14 | — | — | US | disclosed |
| US-6290995-B1 | PRODUCING A PHARMACEUTICAL COMPOSITION OF BAICALIN FROM SCUTELLARIA BAICALENISIS GEORGI OR SCUTOLLARIA SCORDIFOLIA FISCH | XINXIAN ZHAO (US) | 2001-09-18 | — | — | US | disclosed |
| US-6166003-A | Heterocyclic compounds for cancer chemoprevention | LKT LABORATORIES, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-5891633-A | A KIT INCORPORATING THE GENETIC MATERIAL OF THE INVENTION FOR PERFORMING THE SAID METHODS SO AS TO DETERMINE THE PRESENCE OR ABSENCE OF MUTATIONS IN THE DRUG METABOLIZING GENE CYP2C9 AND CYP2A6. | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1995034679-A2 | DEFECTS IN DRUG METABOLISM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-12-21 | — | — | WO | disclosed |
| US-5391568-A | Administering catechin-3-gallate | AMERICAN HEALTH FOUNDATION (US) | 1995-02-21 | — | — | US | disclosed |
| US-5231209-A | Phenylhexyl isothiocyanate | AMERICAN HEALTH FOUNDATION (US) | 1993-07-27 | — | — | US | disclosed |
| US-5114969-A | Method of inhibiting lung tumors, arylalkyl isothiocyanates, and method of synthesizing same | AMERICAN HEALTH FOUNDATION (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175372-A1 | New method for producing antioxidant and prevention of cancer | NFE2L2, PGC, GPX4 | HDAC1 1100/4885HDAC8 779/4885PLOD2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.